Mar 5, 2025 · What the findings suggested: Nicox reported that NCX 470 may improve ocular perfusion and retinal function in damaged eyes (versus vehicle) and—as a result—have therapeutic properties beyond just lowering IOP.

Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Mar 5, 2025 · NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the IOP-lowering effects of NO and prostaglandin analogs (PGAs) and is designed to release bimatoprost and NO into the eye to lower IOP by 2 different pathways in patients with open-angle glaucoma or ocular hypertension.

Mar 20, 2024 · Nicox SA announced results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.

Mar 19, 2025 · NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle...

NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, at clinical stage in dry eye disease. NCX 4251 will be the first topical ophthalmic fluticasone product, a two-week, once-daily treatment leveraging Nicox’s proprietary formulation technology.

The Nutanix Certified Expert - Multicloud Infrastructure (NCX-MCI) tests a candidate’s ability to design enterprise-scale solutions that support business-critical applications with service level agreements specified by business stakeholders.

Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Nov 7, 2022 · Nicox SA today announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure (IOP) in patients with …

Mar 3, 2025 · More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost. New analysis provides additional data demonstrating differentiation of...